Can PFE sustain its earnings momentum into 2025?

**Pfizer's (PFE) prospects for sustaining earnings momentum into 2025 appear promising**, considering the following points: 1. **Strong Financial Performance**: Pfizer's recent financial results have been robust, with a net income of $418 million and a total revenue of $17.76 billion in the most recent quarter. The company's diluted EPS grew by 111.67%, indicating a strong earnings momentum. |code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code| |---|---|---|---|---|---|---|---| |PFE|PFE.N|Pfizer|2024 Q1|-43.79049676025918|-19.51206318294926|-43.298969072164944|169| |PFE|PFE.N|Pfizer|2024 Q2|-97.9469632164243|2.121934343046052|-97.5609756097561|169| |PFE|PFE.N|Pfizer|2024 Q3|288.25757575757575|31.21340152694389|285.7142857142857|169| |PFE|PFE.N|Pfizer|2024 Q4|112.43677476941387|21.914893617021278|111.66666666666667|169| |code|Ticker|Name|Date|Total Revenue|Net Income|market_code| |---|---|---|---|---|---|---| |PFE|PFE.N|Pfizer|2024 Q1|1.4879E10|3.123E9|169| |PFE|PFE.N|Pfizer|2024 Q2|1.3283E10|4.8E7|169| |PFE|PFE.N|Pfizer|2024 Q3|1.7702E10|4.473E9|169| |PFE|PFE.N|Pfizer|2024 Q4|1.7763E10|4.18E8|169| |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |PFE|PFE.N|Pfizer|2024 Q1|-43.298969072164944|0.55|169| |PFE|PFE.N|Pfizer|2024 Q2|-97.5609756097561|0.01|169| |PFE|PFE.N|Pfizer|2024 Q3|285.7142857142857|0.78|169| |PFE|PFE.N|Pfizer|2024 Q4|111.66666666666667|0.07|169| 2. **Analyst Confidence**: The consensus rating for Pfizer is a "Strong Buy" with an average analyst price target of $30.33, suggesting that analysts are optimistic about the company's future performance. 3. **Strategic Initiatives**: Pfizer has been actively transforming its business and focusing on cost reductions and strategic growth opportunities. The company's pipeline progress in oncology and obesity treatments, along with its commitment to innovation, positions it well for long-term growth. 4. **Dividend Sustainability**: Pfizer has a history of consistently paying dividends, with a dividend yield of 5.95% and a forward dividend yield of 6.07% as of the latest data. The company's dividend payout ratio indicates that it retains a significant portion of its earnings, which is beneficial for future growth and stability. 5. **Market Positioning**: Pfizer's strong non-COVID revenue growth and cost optimizations, along with its undervalued status, position it well for sustained earnings momentum. The company's focus on sustainability and social impact through its sustainability bond also enhances its reputation and potential for long-term growth. In conclusion, Pfizer's strong financial performance, analyst confidence, strategic initiatives, dividend sustainability, and market positioning all point to a positive outlook for sustaining earnings momentum into 2025.